RARE Ultragenyx Pharmaceutical Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

RARE [NASD]

Ultragenyx Pharmaceutical Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-7.36	Insider Own	1.80%	Shs Outstand	58.00M	Perf Week	0.26%
Market Cap	5.07B	Forward P/E	-	EPS next Y	-5.00	Insider Trans	-8.32%	Shs Float	56.15M	Perf Month	20.96%
Income	-425.00M	PEG	-	EPS next Q	-1.55	Inst Own	-	Short Float	13.21%	Perf Quarter	64.30%
Sales	121.90M	P/S	41.59	EPS this Y	-79.30%	Inst Trans	3.55%	Short Ratio	13.02	Perf Half Y	97.26%
Book/sh	10.50	P/B	8.22	EPS next Y	22.20%	ROA	-40.40%	Target Price	82.00	Perf Year	47.00%
Cash/sh	11.28	P/C	7.64	EPS next 5Y	17.20%	ROE	-60.50%	52W Range	31.99 - 91.77	Perf YTD	101.97%
Dividend	-	P/FCF	-	EPS past 5Y	-25.90%	ROI	-65.40%	52W High	-6.00%	Beta	2.25
Dividend %	-	Quick Ratio	4.50	Sales past 5Y	-	Gross Margin	95.90%	52W Low	169.65%	ATR	4.17
Employees	740	Current Ratio	4.50	Sales Q/Q	99.50%	Oper. Margin	-	RSI (14)	63.57	Volatility	4.43% 5.35%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-12.90%	Profit Margin	-	Rel Volume	0.45	Prev Close	87.95
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 06 AMC	Payout	-	Avg Volume	569.68K	Price	86.26
Recom	1.80	SMA20	11.01%	SMA50	19.64%	SMA200	60.23%	Volume	257,779	Change	-1.92%

Aug-02-19

Resumed

Wedbush

Outperform

$75

Mar-27-19

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$68 → $83

Feb-22-19

Resumed

Raymond James

Outperform

$80

Jan-02-19

Downgrade

Raymond James

Outperform → Mkt Perform

Nov-08-18

Upgrade

Citigroup

Sell → Neutral

Sep-10-18

Initiated

Morgan Stanley

Equal-Weight

$92

Jun-21-18

Downgrade

Credit Suisse

Outperform → Neutral

May-11-18

Upgrade

Barclays

Equal Weight → Overweight

$62 → $74

May-10-18

Initiated

Goldman

Neutral

$63

Apr-18-18

Upgrade

SunTrust

Hold → Buy

Mar-22-18

Resumed

Piper Jaffray

Overweight

$67

Feb-21-18

Reiterated

Stifel

Buy

$85 → $74

Jan-22-18

Upgrade

Evercore ISI

In-line → Outperform

Jan-18-18

Initiated

Credit Suisse

Outperform

$67

Dec-05-17

Reiterated

Barclays

Equal Weight

$60 → $62

Dec-04-17

Upgrade

Jefferies

Hold → Buy

Sep-14-17

Upgrade

Wedbush

Neutral → Outperform

$62

Aug-23-17

Downgrade

SunTrust

Buy → Hold

$55

Aug-17-17

Initiated

Evercore ISI

In-line

$63

Aug-08-17

Reiterated

H.C. Wainwright

Neutral

$72 → $75

Jul-02-20 08:41AM	Ultragenyx (RARE) Looks Good: Stock Adds 8.2% in Session Zacks
Jul-01-20 12:11PM	Ultragenyx's Dojolvi Gets FDA Nod to Treat Rare Disease Zacks +8.22%
07:52AM	Ultragenyx gets second FdA approval in June MarketWatch
Jun-30-20 03:01PM	Ultragenyx Announces U.S. FDA Approval of Dojolvi (UX007/triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders GlobeNewswire +6.19%
Jun-23-20 12:20PM	Ultragenyx Pharmaceutical Inc (RARE): Hedge Funds In Wait-and-See Mode Insider Monkey
Jun-19-20 01:16PM	FDA grants a second approval to Ultragenyx drug for rare disease MarketWatch +7.92%
10:13AM	Ultragenyx Gets FDA Nod for Label Expansion of Crysvita Zacks
Jun-18-20 01:16PM	Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita® (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO) GlobeNewswire
Jun-11-20 10:21AM	Utragenyx Shares Soar Above 60% YTD on Pipeline Developments Zacks -6.80%
Jun-05-20 11:31AM	Why Is Ultragenyx (RARE) Up 10.7% Since Last Earnings Report? Zacks
May-28-20 08:30AM	Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
May-21-20 08:30AM	Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics GlobeNewswire
May-15-20 08:00AM	Ultragenyx Announces Positive Data from Confirmatory Cohort of Phase 1/2 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) GlobeNewswire +10.13%
May-13-20 04:01PM	Ultragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency GlobeNewswire
May-11-20 04:02PM	Ultragenyx to Present at BofA Securities Global Health Care Conference GlobeNewswire +5.51%
09:21AM	Analyst Estimates: Here's What Brokers Think Of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter Report Simply Wall St.
May-07-20 07:13PM	Edited Transcript of RARE earnings conference call or presentation 6-May-20 9:00pm GMT Thomson Reuters StreetEvents
04:01PM	Ultragenyx Pharmaceutical Inc (RARE) Q1 2020 Earnings Call Transcript Motley Fool
10:12AM	Ultragenyx (RARE) Q1 Earnings & Sales Fall Short of Estimates Zacks
May-06-20 06:35PM	Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:01PM	Ultragenyx Reports First Quarter 2020 Financial Results and Corporate Update GlobeNewswire
11:47AM	Will Ultragenyx Pharmaceutical Continue to Surge Higher? Zacks
May-04-20 08:30AM	GeneTx and Ultragenyx Announce GTX-102 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome GlobeNewswire +10.35%
Apr-30-20 04:05PM	Ultragenyx to Host Conference Call for First Quarter 2020 Financial Results and Corporate Update GlobeNewswire -5.04%
11:12AM	Alkermes' (ALKS) Q1 Earnings Increase Y/Y, Revenues Beat Zacks
09:26AM	Is a Surprise Coming for Ultragenyx (RARE) This Earnings Season? Zacks
Apr-28-20 06:28PM	Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2020 Virtual Annual Meeting GlobeNewswire -7.64%
Apr-27-20 12:32PM	Ultragenyx (RARE) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Apr-01-20 09:37AM	Ultragenyx Inks Deal With Daiichi For Gene Therapy Platform While Also Extending Cash Runway SmarterAnalyst +5.58%
Mar-31-20 08:00PM	Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology GlobeNewswire
04:05PM	REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder GlobeNewswire
Mar-29-20 12:12PM	Hedge Funds Were Selling Ultragenyx Pharmaceutical Inc (RARE) Before The Coronavirus Insider Monkey
Mar-21-20 10:39AM	Have Insiders Been Buying Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares This Year? Simply Wall St.
Mar-16-20 08:30AM	GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome GlobeNewswire -22.01%
Mar-14-20 11:30AM	Ultragenyx (RARE) Down 31.1% Since Last Earnings Report: Can It Rebound? Zacks
Mar-09-20 05:10PM	Ultragenyx to Present at Barclays Global Healthcare Conference GlobeNewswire -9.28%
Mar-03-20 04:15PM	Ultragenyx Announces Planned Transition of Chief Financial Officer GlobeNewswire
Feb-27-20 08:00AM	Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO) GlobeNewswire
Feb-21-20 08:30AM	Ultragenyx to Present at SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-18-20 11:20PM	Edited Transcript of RARE earnings conference call or presentation 13-Feb-20 10:00pm GMT Thomson Reuters StreetEvents
Feb-14-20 09:18AM	Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q4 Zacks
Feb-13-20 04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update GlobeNewswire
Feb-06-20 04:01PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2019 Financial Results and Corporate Update GlobeNewswire
Feb-05-20 05:19AM	How Should Investors Feel About Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Pay? Simply Wall St.
Jan-16-20 07:22AM	The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics Benzinga
Jan-15-20 04:01PM	GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman Syndrome GlobeNewswire
Jan-14-20 08:53AM	Ultragenyx Provides Preliminary Crysvita 2019 Revenues Zacks +6.68%
Jan-13-20 10:14AM	Ultragenyx's Gene Therapy Positive in Genetic Disorder Study Zacks +6.60%
08:10AM	Ultragenyx Reports Preliminary 2019 Revenue and Provides 2020 Crysvita Revenue Guidance GlobeNewswire
08:00AM	Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO) GlobeNewswire
Jan-10-20 07:13AM	The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx Benzinga +23.39%
Jan-09-20 04:01PM	Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency GlobeNewswire
Dec-29-19 09:40PM	Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus Benzinga
Dec-19-19 08:30AM	Ultragenyx to Present at 38 Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-18-19 08:30AM	Ultragenyx Announces Sale of Future European Royalties on Crysvita® (burosumab) for $320 Million to Royalty Pharma GlobeNewswire
Dec-10-19 09:11PM	Do Hedge Funds Love Ultragenyx Pharmaceutical Inc (RARE)? Insider Monkey
Dec-05-19 04:32PM	Astellas-Audentes Deal Likely to Ignite More Acquisitions GuruFocus.com
11:31AM	Ultragenyx (RARE) Up 13.6% Since Last Earnings Report: Can It Continue? Zacks
Dec-03-19 10:15AM	Companies Like Ultragenyx Pharmaceutical (NASDAQ:RARE) Are In A Position To Invest In Growth Simply Wall St. +6.18%
Nov-26-19 08:30AM	Ultragenyx to Present at Piper Jaffray 31st Annual Healthcare Conference GlobeNewswire
Nov-09-19 10:43AM	Edited Transcript of RARE earnings conference call or presentation 5-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-08-19 10:02AM	After sons rare disease diagnosis, father finds hope through film festival American City Business Journals
08:30AM	Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
Nov-06-19 11:00AM	Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q3 Zacks -5.87%
Nov-05-19 05:35PM	Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:01PM	Ultragenyx Reports Third Quarter 2019 Financial Results and Corporate Update GlobeNewswire
Oct-30-19 08:30AM	Ultragenyx to Host Conference Call for Third Quarter 2019 Financial Results and Corporate Update GlobeNewswire
Oct-28-19 10:32AM	Ultragenyx (RARE) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Oct-26-19 02:55PM	Were Hedge Funds Right About Dumping Ultragenyx Pharmaceutical Inc (RARE)? Insider Monkey
Oct-18-19 10:23AM	These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year American City Business Journals
10:19AM	Those Who Purchased Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Three Years Ago Have A 34% Loss To Show For It Simply Wall St.
Oct-15-19 10:57AM	Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA Zacks
Oct-14-19 08:30AM	Ultragenyx Announces FDA Accepts New Drug Application for UX007 (triheptanoin) for Treatment of Long-chain Fatty Acid Oxidation Disorders GlobeNewswire
Oct-02-19 08:31AM	Ultragenyx Gets FDA Approval for Label Expansion of Crysvita Zacks
08:30AM	Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit GlobeNewswire
Sep-30-19 08:30AM	Ultragenyx and Kyowa Kirin Announce U.S. FDA Approves Label Update for Crysvita® (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH) GlobeNewswire
Sep-11-19 03:15PM	Ultragenyx Pharmaceutical Inc (RARE) President & CEO Emil D Kakkis Bought $218,150 of Shares GuruFocus.com
11:37AM	Ultragenyx to Submit sBLA for Label Expansion of Crysvita Zacks
Sep-10-19 09:00AM	Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) in Tumor-Induced Osteomalacia (TIO) GlobeNewswire
Sep-04-19 09:42AM	Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA Zacks -12.15%
04:00AM	Ultragenyx Announces Positive Data from Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia GlobeNewswire
Sep-03-19 12:38PM	Is Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Trading At A 36% Discount? Simply Wall St. -5.84%
08:30AM	GeneTx and Ultragenyx Announce Orphan Drug Designation and Rare Pediatric Disease Designation for GTX-102 GlobeNewswire
Aug-31-19 09:32AM	Ultragenyx (RARE) Down 9.9% Since Last Earnings Report: Can It Rebound? Zacks
Aug-30-19 08:30AM	Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
Aug-23-19 07:36AM	Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues Zacks
Aug-15-19 04:35PM	This Biotech Stock Just Roped In A New Partner And A Potential Buyout Investor's Business Daily
Aug-14-19 08:30AM	Ultragenyx Announces Partnership with GeneTx to Advance Treatment for Angelman Syndrome GlobeNewswire
Aug-13-19 08:30AM	Ultragenyx to Present at Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-12-19 10:59AM	Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View Zacks
Aug-10-19 11:18AM	Edited Transcript of RARE earnings conference call or presentation 1-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-02-19 10:28AM	Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q2 Zacks -7.89%
01:24AM	Ultragenyx Pharmaceutical Inc (RARE) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 05:55PM	Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM	Ultragenyx Reports Second Quarter 2019 Financial Results and Corporate Update GlobeNewswire
08:30AM	Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders GlobeNewswire
Jul-25-19 10:34AM	Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-23-19 08:30AM	Ultragenyx to Host Conference Call for Second Quarter 2019 Financial Results and Corporate Update GlobeNewswire
Jul-17-19 10:20AM	Why Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Is A Financially Healthy Company Simply Wall St.
Jul-15-19 08:30AM	Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D. GlobeNewswire

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia. In addition, the company is developing UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Arcturus Therapeutics Holdings Inc. to develop additional nucleic acid therapies for rare diseases. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Huizenga Theodore Alan	SVP, Controller and PAO	Jul 08	Option Exercise	21.00	2,000	42,000	18,582	Jul 10 05:21 PM
Huizenga Theodore Alan	SVP, Controller and PAO	Jul 08	Sale	91.00	2,638	240,058	16,582	Jul 10 05:21 PM
Fust Matthew K	Director	Jul 06	Option Exercise	21.00	6,181	129,801	19,731	Jul 08 12:30 PM
Fust Matthew K	Director	Jul 06	Sale	90.00	6,181	556,290	13,550	Jul 08 12:30 PM
Huizenga Theodore Alan	SVP, Controller and PAO	Jul 01	Option Exercise	21.00	1,500	31,500	18,720	Jul 06 02:21 PM
Fust Matthew K	Director	Jul 01	Option Exercise	21.00	5,000	105,000	18,550	Jul 06 02:21 PM
Fust Matthew K	Director	Jul 01	Sale	85.00	5,000	425,000	13,550	Jul 06 02:21 PM
Huizenga Theodore Alan	SVP, Controller and PAO	Jul 01	Sale	81.00	2,611	211,491	17,220	Jul 06 02:21 PM
Sharp Shalini	CFO & Executive Vice President	Jun 04	Option Exercise	48.43	2,564	124,175	103,772	Jun 05 04:59 PM
Sharp Shalini	CFO & Executive Vice President	Jun 04	Sale	74.01	2,564	189,762	101,208	Jun 05 04:59 PM
Sharp Shalini	CFO & Executive Vice President	Jun 03	Option Exercise	48.43	10,234	495,633	111,442	Jun 05 04:59 PM
Sharp Shalini	CFO & Executive Vice President	Jun 03	Sale	74.23	10,234	759,670	101,208	Jun 05 04:59 PM
Huizenga Theodore Alan	SVP, Controller and PAO	May 26	Sale	74.93	260	19,482	18,331	May 27 03:14 PM
Sharp Shalini	CFO & Executive Vice President	May 19	Option Exercise	60.57	7,128	431,710	104,851	May 20 07:49 PM
Sharp Shalini	CFO & Executive Vice President	May 19	Sale	73.32	7,128	522,625	100,944	May 20 07:49 PM
Sharp Shalini	CFO & Executive Vice President	May 18	Option Exercise	70.57	19,593	1,382,678	122,929	May 20 07:49 PM
Aliski William	Director	May 18	Option Exercise	40.37	7,500	302,775	55,424	May 20 07:50 PM
Aliski William	Director	May 18	Sale	74.65	7,500	559,875	47,924	May 20 07:50 PM
Sharp Shalini	CFO & Executive Vice President	May 18	Sale	73.33	21,985	1,612,260	100,944	May 20 07:49 PM
Aliski William	Director	May 18	Sale	74.02	20,000	1,480,322	70,350	Jun 03 04:26 PM
Fust Matthew K	Director	May 18	Sale	75.00	1,875	140,625	11,000	May 19 07:13 PM
Parschauer Karah Herdman	EVP and General Counsel	May 18	Sale	74.72	2,722	203,374	27,312	May 19 07:12 PM
Huizenga Theodore Alan	SVP, Controller and PAO	May 15	Option Exercise	21.00	1,500	31,500	20,219	May 19 07:15 PM
Huizenga Theodore Alan	SVP, Controller and PAO	May 15	Sale	71.00	2,461	174,731	18,719	May 19 07:15 PM
Fust Matthew K	Director	Apr 22	Sale	65.00	1,875	121,875	12,875	Apr 24 01:00 PM
Huizenga Theodore Alan	SVP, Controller and PAO	Jan 14	Sale	61.00	1,000	61,000	15,946	Jan 15 01:08 PM
Sharp Shalini	CFO & Executive Vice President	Sep 16	Option Exercise	5.54	31,843	176,317	99,089	Sep 17 07:25 PM
KAKKIS EMIL D	President & CEO	Sep 11	Buy	43.63	5,000	218,150	472,479	Sep 11 12:35 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience